Analytical Data
-
Gene name
PSMC6
- Application
-
Alternative Names
CADP44; P44; SUG2; p42; 26S proteasome AAA-ATPase subunit RPT4; Proteasome 26S subunit ATPase 6; Proteasome subunit p42
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62333
-
Expression Region
Ala2~Val403
-
Molecular Weight
46kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMC6, a key component of the 26S proteasome, plays a crucial role in the degradation of ubiquitinated proteins, thereby regulating various cellular processes such as the cell cycle, signaling pathways, and stress responses. Due to its involvement in protein homeostasis and potential links to numerous diseases, including cancer and neurodegenerative disorders, PSMC6 has garnered significant interest in biomedical research. The recombinant protein of PSMC6 is essential for studying its structure-function relationship, understanding its mechanistic role in the proteasome, and exploring its interactions with other proteasomal components. Advances in biotechnological methods have enabled the production of functional recombinant PSMC6, facilitating investigations into its enzymatic activity and regulatory mechanisms. Furthermore, the characterization of PSMC6 may contribute to the development of targeted therapeutic strategies aimed at modulating proteasome activity, offering potential applications in treating various pathologies linked to proteasomal dysfunction. Overall, the study of PSMC6 recombinant protein represents a vital avenue for enhancing our understanding of proteasomal regulation and its implications for cellular health and disease.
